BMRA News and Press, Biomerica Inc. From 05/12/21

Second Sight Medical Products (EYES) +24% on reporting two-year results of its Orion study.Upstart Holdings (UPST) +23% on Q1 results.Minerva Neurosciences (NERV) +23% on Q1 results.fuboTV Inc. (FUBO) +21% on Q1 results.Biomerica (BMRA) +17%.Lucira Health (LHDX) +16% ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investors, and get ready for another busy day of trading! We’re back at it again with a look at the biggest pre-market stock movers for Wednesday. Expect a lot of earnings news to be affecting stock as ...

Biomerica's (BMRA) new COVID-19 Antigen Rapid Test can now be performed with a simple less invasive nasal swab.This simple nasal swab, which takes the sample from the front opening of the nose, is less invasive and more comfortable for patients than the deep anterior nasal swab which is typic...

Less invasive nasal swab taken from front opening of the nose is more comfortable for patients Test can be performed by doctors, school and company nurses, and medical assistants, in any location without specialized equipment IRVINE, Calif., May 11, 2021 (GLOBE NEWSWIRE)...

Biomerica Inc. (NASDAQ:BMRA) traded at a new 52-week low today of $4.23. Approximately 1.3 million shares have changed hands today, as compared to an average 30-day volume of 147,000 shares. Biomerica Inc is engaged in the development, manufacturing, and marketing medical diagnostic prod...

Biomerica Inc. (NASDAQ:BMRA) traded today at a new 52-week low of $4.38. So far today approximately 1.3 million shares have been exchanged, as compared to an average 30-day volume of 123,000 shares. Biomerica Inc is engaged in the development, manufacturing, and marketing medical diagnos...

Biomerica (BMRA): FQ3 Revenue of $3.62M (+206.8% Y/Y) beats by $1.12M.Shares -2.15%.Press Release For further details see: Biomerica beats on revenue

Sales increase driven by first sales of COVID-19 Antigen Rapid Test in Europe after January 2021 CE Mark approval Awarded two new patents for InFoods ® diagnostic guided therapy technology, including the first Japanese patent InFoods ® IBS diagnostic-guid...

Biomerica (BMRA): FQ2 Net Loss of $1.49M.Revenue of $1.37M (-14.4% Y/Y).Business Updates:Biomerica expects completion of enrollment of its Irritable Bowel Syndrome Diagnostic-Guided Therapy clinical trial by end of April, 2021The company says FDA is actively reviewing its EUA submission ...

Biomerica expects completion of enrollment of its Irritable Bowel Syndrome Diagnostic-Guided Therapy clinical trial by end of April, 2021 FDA actively reviewing Company’s EUA submission for its first of its kind “at-home” Blood Collection kit used with the...